EGFR-antibody-nanostructures carrying KRAS-siRNA, but not control-siRNA treated cells showed marked reduction of KRAS protein expression levels in EGFR-positive NSCLC cell lines A549 and A427 as determined by Western blot analysis (Fig. 5B). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.